At Sesen Bio, we are committed to renewing life for people with cancer. We are a late-stage clinical company advancing fusion protein therapies based on our Targeted Protein Therapeutics platform. Our lead program, Viciniumâ˘, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer. Twelve-month data from the trial are anticipated in mid-2019. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells while sparing healthy cells. Source
No articles found.
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
Allied Healthcare Products, Inc. is a leading manufacturer of medical gas construc...
Allied Healthcare Products, Inc. is a leading m...
Lisaiceland is here to bring you a fully blockchained, democratized, healthcare AI...
Lisaiceland is here to bring you a fully blockc...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Otonomy is a biopharmaceutical company dedicated to the development of innovative ...
Otonomy is a biopharmaceutical company dedicate...
CohBar, Inc. is a leader in the research and development of mitochondria based the...
CohBar, Inc. is a leader in the research and de...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.